Key facts
- Ansa Biotechnologies’s last known valuation is $269.0M (Oct 2025).
- It has raised $139.6M across 4 recorded rounds; the latest was Early Stage VC ($46.4M) in Jun 2024.
- Notable investors include Y Combinator, US National Science Foundation, Mubadala Investment Company, Metaplanet Holdings, RA Capital Management — 27 tracked in total.
- Ansa Biotechnologies has filed 6 Form Ds with the SEC since 2020, most recently Dec 2025 ($46.4M sold to 41 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for Ansa Biotechnologies
Funding rounds
4 roundsAbout Ansa Biotechnologies
Developer of a novel DNA synthesis technology designed to simplify the biological research process. The company's enzymatic technology accelerates biological research and engineering based on polymerase-nucleotide conjugates to extend a molecule, which produces gene-length oligonucleotides, enabling medical researchers to make synthetic genes for customers as a service.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Emeryville, CA, United States
- Founded
- 2018
- Employees
- 77
- Website
- ansabio.com/
- Ownership
- Privately Held (backing)
Ansa Biotechnologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ansa Biotechnologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ansa Biotechnologies in its N-PORT filings yet. We sweep new filings monthly.